Pharma's Market
SPECIAL REPORT
MOST SHARED
- Marc Faber: 100% Chance of Global Recession
- Time for Flash Sales to Adapt or Die
- How to Trade on the Jobs Report
- Citigroup Lost $20 Million on Facebook IPO Trades
- Don’t Trust Buybacks
- Buy Broken Stocks, Not Broken Companies
- The Biggest Market Myth There Is?
- Facebook: The Song — Yes, We're Serious
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Buying the Right Sell-Off Stocks
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Citigroup Lost $20 Million on Facebook IPO Trades
- Sticker Shock: What College Is Likely to Cost in 18 Years
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- Icahn Raises Stake in Chesapeake, Wants Board Seats
- Marc Faber: Chance of Global Recession Is Now 100%
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- What Happened to Stocks? Most Unloved in 50 Years
- Cool Jobs: From Gold Stacker to Bed Tester
- Many Greeks Moved Their Money Abroad Long Ago
RSS FEED
Orexigen And Its Obesity Bets
Text Size 
Reporter
 |
OREX[OREX
Loading...
()
] is one of those companies that tries to turn trash into treasure. In other words, it takes old, generic drugs and mixes them together to hopefully do new things. Orexigen actually has two diet drugs in mid- to late-stage development. The one that's furthest along is Contrave. It's a combination of a drug for alcoholism and smoking cessation. Orexigen is aiming the drug at mild to moderately obese women.
In one study patients lost as much as 11 percent of their body weight in as many months. But as many as 30 percent of patients got nauseous.
OREX may have Phase 3 test results on Contrave late this year or early next. Graham Cooper, the CFO, strongly hinted at the breakout that the data could be released at the huge JPMorgan Healthcare Conference in January. OREX plans to file for FDA approval of the drug in late 2009.
Cooper also said the company will likely want to find a corporate partner with a big sales force for Contrave once the first Phase 3 results come out. "The time to do that (collaboration discussions) is once we open the envelope (on the test results) and see who shows up (potential interested partners)," Cooper said.
The second diet pill is called Empatic. It's a combo of the same stop-smoking drug and an epilepsy treatment. The company thinks it's probably best suited for very obese older men and women. In one test patients shed 15 percent of their weight over 11 months.
Orexigen expects to move Empatic into a big, late-stage clinical trial late next year.
Amylin [AMLN
Loading...
()
]is up next. This is its first investment conference presentation since the latest Byetta safety news broke. The CEO, Dan Bradbury, is not here, though.
Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
